REC-4881 An investigational oral MEK1/2 inhibitor in Phase 2 development for reducing polyp burden in familial adenomatous polyposis.
Visit productCosigns Received
Be the first Cosign
Put your name behind REC-4881.
Add it to your Products I use list and share why you use it.